NASDAQ$THRD
Third Harmonic Bio Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Financial results announced for fourth quarter and year-end 2022.
Third Harmonic Bio reported its Q4 and year-end 2022 financial results, highlighting progress in preclinical development of a next-generation oral KIT inhibitor for mast cell-mediated inflammatory diseases. The company's cash and cash equivalents totaled $288.9 million as of December 31, 2022.
- Progressing preclinical next-generation oral KIT Inhibitor for Mast Cell-Mediated Inflammatory Diseases.
- Observed promising preliminary clinical activity in Phase 1b clinical trial of THB001.
- Discontinued Phase 1b clinical trial of THB001 in chronic inducible urticaria following observation of asymptomatic liver transaminitis in two subjects.
- Making meaningful progress toward selecting a next-generation KIT inhibitor development candidate in 2023.
Headline financials
Revenue & EPS history
Third Harmonic · Revenue · Quarterly
$0
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 5 quarterly earnings reports
+1.0%
Avg return
Earnings day
+14.2%
Avg return
5 days after
+13.0%
Avg return
30 days after
40%
6 / 15 earnings
Positive
+13.0%
Q3 2024
Best reaction
-11.1%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2025 | +0.6% | -0.2% | +5.8% | |
| Q4 2024 | -1.1% | +42.1% | +41.9% | |
| Q3 2024 | +13.0% | +13.0% | -11.2% | |
| Q2 2024 | +10.6% | +11.5% | +9.2% | |
| Q1 2024 | +10.2% | +11.8% | +3.3% | |
| Q4 2023 | +8.0% | +7.1% | +29.2% | |
| Q3 2023 | +0.8% | — | — | |
| Q2 2023 | -6.4% | — | — | |
| Q1 2023 | -11.1% | — | — | |
| Q4 2022 | -3.5% | — | — | |
| Q3 2021 | -1.2% | — | — | |
| Q4 2021 | -1.2% | — | — | |
| Q3 2022 | -1.2% | — | — | |
| Q1 2022 | -1.2% | — | — | |
| Q2 2022 | -1.2% | — | — | |
| Q2 2021 | — | — | — | |
| Q1 2021 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro